AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02778594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Nebicapone matching placebo tablets
Study NCT02778594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levodopa 100 mg / benserazide 25 mg
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
Study NCT02778594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: levodopa 100 mg / benserazide 25 mg
Description: Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
Study NCT01688362 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP)
Description: Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
Study NCT01688362 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid
Description: Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.~For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site.
Study NCT00298766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VELCADE
Description: Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2~Or~Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2
Study NCT05493579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implant supported overdenture
Description: Implant supported overdenture compared to complete denture
Study NCT00581724 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telephone interview or self report survey.
Description: We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
Study NCT04035356 — intervention group
Intervention type: DEVICE
Intervention: Aortic valve repair
Description: Use of a HAART Aortic Annuloplasty Device in patients undergoing aortic valve repair surgery
Study NCT03604094 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasonographic evaluation
Description: Right internal jugular vein will be evaluated with ultrasound for anatomical variations and dimensions
Study NCT04950491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Modified Dental Anxiety Score (MDAS) questionnaire
Description: MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
Study NCT04950491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Dental Anxiety Score (MDAS) questionnaire
Description: MDAS was used to measure the patients' anxiety toward dental treatment before implant surgery (Humphris, Dyer, \&Robinson, 2009). Originally, the MDAS questionnaire included five questions answered with a 5-category Likert scale. The original MDAS questionnaire does not cover anxiety toward implant surgery. Therefore, a question enquiring about patients' feelings towards implant surgery was added.
Study NCT04950491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain questionnaire
Description: Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
Study NCT04950491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain questionnaire
Description: Patients were asked to describe the worst pain feeling using a standard 10 cm Visual Analog Scale (VAS) and the proportion of time spent in severe pain using a 5 category Likert scale. The number of analgesics taken per day was also asked.
Study NCT04950491 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral Health-Related Quality of Life (OHRQoL) questionnaire
Description: The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
Study NCT04950491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Health-Related Quality of Life (OHRQoL) questionnaire
Description: The OHRQoL comprises 14 questions covering problems the patient may in three main categories: oral function, daily activity, and post-operative symptoms (Chaushu, Becker, Zeltser, Vasker, \& Chaushu, 2004). Patients answered using a 5-category Likert scale.
Study NCT01496924 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: speech therapy
Description: A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
Study NCT01434498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-5885 tablet
Description: GS-5885 tablet, 90 mg, QD
Study NCT01434498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GS-9451 tablet
Description: GS-9451 tablet, 200 mg QD
Study NCT01434498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tegobuvir capsule
Description: tegobuvir capsule, 30 mg BID
Study NCT01434498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin tablet
Description: ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
Study NCT01434498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo matching ribavirin tablet
Description: placebo matching ribavirin tablet, BID
Study NCT01434498 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: placebo matching tegobuvir capsule
Description: placebo matching tegobuvir capsule, BID
Study NCT02816255 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Full Face Mask with same CPAP Pressure
Description: Full Face Mask with same CPAP Pressure
Study NCT02816255 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Full Face Mask with new Pressure
Description: New cpap pressure derived from our formula for the final two weeks.
Study NCT02695758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Study NCT02695758 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine extended-release liposome injection
Study NCT00508001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: ZD6474 300mg
Study NCT00508001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: ZD6474 100 mg
Study NCT00508001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Placebo + Best Supportive Care
Study NCT01591577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lapatinib/Temozolomide/radiation
Description: Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
Study NCT04419558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamrevlumab
Description: Sterile solution for injection
Study NCT04419558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile solution for injection
Study NCT01552408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3 mg ranibizumab
Description: Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
Study NCT01552408 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3 mg ranibizumab
Description: Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
Study NCT01552408 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Targeted Pan Retinal Photocoagulation
Description: Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
Study NCT03162302 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic Resonance Imaging (MRI)
Description: Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
Study NCT00804596 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Apollo Blood Glucose Monitoring System
Description: Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
Study NCT01663155 — intervention group
Intervention type: DEVICE
Intervention: chest x-ray with or without CAD, lose dose CT scan
Description: PA view, low dose CT scan
Study NCT04071899 — intervention group
Intervention type: OTHER
Intervention: Scale vaidation
Description: It's just filling a scale in order to validate it in French
Study NCT02219750 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: switch twice-daily insulin
Description: compare two different insuiln regimen in basal insuln base and premixed insulin.~NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin
Study NCT03649997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will be administered JNJ-61393215-matching placebo in Part 1, 2 and 3 of study as oral suspension.
Study NCT01504204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + benzoyl peroxide samples
Description: A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
Study NCT01504204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene + benzoyl peroxide from standard tube
Description: Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
Study NCT01504204 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene + benzoyl peroxide from standard tube
Description: Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
Study NCT03603691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: BMRC manual muscle test
Description: muscle scale grades muscle power on a scale of 0 to 5 in relation to the maximum expected for that muscle
Study NCT03603691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MicroFET2 handhold dynamometer
Description: MicroFET 2 Handheld Dynamometer is a force evaluation testing device to evaluate the strength of various muscle groups
Study NCT03603691 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Modified Tardieu Scale
Description: Modified Tardieu Scale is to measure if there is spasticity present in a person's muscle and its response to movement
Study NCT03513562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03513562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03513562 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pralsetinib
Description: Administered orally
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered IV
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered IV
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered IV
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered IV
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Administered IV
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered IV
Study NCT04222972 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Administered IV
Study NCT02180035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Symbiotic
Description: 6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
Study NCT02180035 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin (placebo for symbiotic)
Description: 6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
Study NCT02180035 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention
Description: Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
Study NCT02180035 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
Study NCT00686894 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PDUS
Description: PDUS scored for each enthesitis every 2 weeks for 24 weeks.
Study NCT03649997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-61393215
Description: Participants will be administered JNJ-61393215 in Part 1, 2 and 3 of study as capsule.
Study NCT00686894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: * 5 mg/kg~* IV~* Frequency : weeks 0,2,6
Study NCT01059955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Phosphate Ophthalmic Solution (EGP-437)
Description: Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
Study NCT01059955 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone phosphate ophthalmic solution
Description: Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
Study NCT03365401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: decompression surgery
Description: undertake decompression surgery
Study NCT03365401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nonsurgical treatment
Description: complete on bed with prevention of complication
Study NCT03964311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emergency Room Evaluation Tool (ER2)
Description: Emergency Room Evaluation Tool represents a screening method that will be used at the Emergency by nurses. This tool evaluates the health conditions of all the patients who are 75 years and over.
Study NCT03364530 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine-Oxaliplatin Regimen
Description: Vascularisation of hepatic tumors is almost exclusively provided by the hepatic artery.~Gemcitabine and oxaliplatin have a high rate of hepatic extraction during the first passage, thus allowing the drugs to reach high intra-tumoral concentrations with low systemic toxicity.
Study NCT03364530 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Hepatic intra arterial chemotherapy
Description: The implantation of a hepatic arterial catheter has now been mastered by interventional radiologists and makes it possible to increase the intra-tumoral concentration of the drugs and probably to limit their systemic toxicity.~Very recently, we have reported that this combination in progressive IHC following systemic gemcitabine/oxaliplatin has led to partial responses and allowed certain patients to benefit from curative treatment.~This suggests that the intra-arterial approach increases the efficacy of these 2 drugs. For locally-advanced IHC, such a loco-regional approach is worth exploring in this poor-prognosis tumor.
Study NCT04212234 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound propagation velocities, ultrasound fetal quality
Description: Obese pregnant women will be included before the second trimester fetal ultrasound examination.~Women will be allocated to one intervention group or to the control group. In the intervention group, the ultrasonographer will be able to use several ultrasound propagation velocities to perform the exam.~In the control group, exam will be performed using the conventional ultrasound velocity.~An exam will be considered to be complete if all the images recommended by national guideline are acquired. If ultrasound images are missing, other ultrasound exams may be performed until completeness is reached.~The protocol will be applied for the second and the third fetal ultrasound examination which are recommended by national guideline.~All scans will be evaluated by two independent experts who do not have performed any of the exams. They will evaluate the completeness of each exam. Each scan will be quoted using the quality score proposed by Salomon et al.
Study NCT03713242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg
Description: Administered as a tablet.
Study NCT03713242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACT-541468 25 mg (or 10 mg depending on interim results)
Description: Administered as a tablet.
Study NCT03470506 — intervention group
Intervention type: OTHER
Intervention: Stool Samples
Description: Stool samples will be collected at baseline and 3 months to assess differences in microbiome composition between groups